Trial Profile

Phase IA and IB Study of AAVrh.10hFXN Gene Therapy for the Cardiomyopathy of Friedreich's Ataxia

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 22 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs LX 2006 (Primary) ; Prednisone (Primary)
Indications Cardiomyopathies; Friedreich's ataxia
Focus Adverse reactions

Most Recent Events

17 Oct 2024 Planned number of patients changed from 10 to 25.
15 Jul 2024 According to a LEXEO Therapeutics Media Release, Weill Cornell investigator-initiated trial is currently enrolling in Cohort 2.
09 May 2024 According to Lexeo Therapeutics, Inc. media release, the company has completed in-license agreement with Cornell University for intellectual property rights, including current and future clinical data from an ongoing investigator-initiated trial of AAVrh.10hFXN (LX2006) to support regulatory discussions.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com